Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells

Abstract Mesenchymal stem cells (MSC) have been extensively studied over the past years for the treatment of different diseases. Most of the ongoing clinical trials currently involve the use of MSC derived from adult tissues. This source may have some limitations, particularly with therapies that ma...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Luzzani, Carlos D. [verfasserIn] Miriuka, Santiago G. [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2016

Schlagwörter:	Pluripotent stem cells Embryonic stem cells Cell reprogramming Mesenchymal stem cells Mesenchymal stromal cells Differentiation Pluripotent-derived mesenchymal stem cells iPS-derived mesenchymal stem cells Epithelial-to-mesenchymal transition EMT

Übergeordnetes Werk:	Enthalten in: Stem cell reviews - New York, NY : Springer, 2005, 13(2016), 1 vom: 05. Nov., Seite 68-78
Übergeordnetes Werk:	volume:13 ; year:2016 ; number:1 ; day:05 ; month:11 ; pages:68-78

Links:	Volltext

DOI / URN:	10.1007/s12015-016-9695-z

Katalog-ID:	SPR023690429

Internformat


LEADER	01000caa a22002652 4500
001	SPR023690429
003	DE-627
005	20230519163820.0
007	cr uuu---uuuuu
008	201006s2016 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s12015-016-9695-z \|2 doi
035			\|a (DE-627)SPR023690429
035			\|a (SPR)s12015-016-9695-z-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 570 \|a 610 \|q ASE
084			\|a 42.15 \|2 bkl
100	1		\|a Luzzani, Carlos D. \|e verfasserin \|4 aut
245	1	0	\|a Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells
264		1	\|c 2016
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract Mesenchymal stem cells (MSC) have been extensively studied over the past years for the treatment of different diseases. Most of the ongoing clinical trials currently involve the use of MSC derived from adult tissues. This source may have some limitations, particularly with therapies that may require extensive and repetitive cell dosage. However, nowadays, there is a staggering growth in literature on a new source of MSC. There is now increasing evidence about the mesenchymal differentiation from pluripotent stem cell (PSC). Here, we summarize the current knowledge of pluripotent-derived mesenchymal stem cells (PD-MSC). We present a historical perspective on the subject, and then discuss some critical questions that remain unanswered.
650		4	\|a Pluripotent stem cells \|7 (dpeaa)DE-He213
650		4	\|a Embryonic stem cells \|7 (dpeaa)DE-He213
650		4	\|a Cell reprogramming \|7 (dpeaa)DE-He213
650		4	\|a Mesenchymal stem cells \|7 (dpeaa)DE-He213
650		4	\|a Mesenchymal stromal cells \|7 (dpeaa)DE-He213
650		4	\|a Differentiation \|7 (dpeaa)DE-He213
650		4	\|a Pluripotent-derived mesenchymal stem cells \|7 (dpeaa)DE-He213
650		4	\|a iPS-derived mesenchymal stem cells \|7 (dpeaa)DE-He213
650		4	\|a Epithelial-to-mesenchymal transition \|7 (dpeaa)DE-He213
650		4	\|a EMT \|7 (dpeaa)DE-He213
700	1		\|a Miriuka, Santiago G. \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Stem cell reviews \|d New York, NY : Springer, 2005 \|g 13(2016), 1 vom: 05. Nov., Seite 68-78 \|w (DE-627)494833777 \|w (DE-600)2197218-7 \|x 1558-6804 \|7 nnns
773	1	8	\|g volume:13 \|g year:2016 \|g number:1 \|g day:05 \|g month:11 \|g pages:68-78
856	4	0	\|u https://dx.doi.org/10.1007/s12015-016-9695-z \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_224
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2005
936	b	k	\|a 42.15 \|q ASE
951			\|a AR
952			\|d 13 \|j 2016 \|e 1 \|b 05 \|c 11 \|h 68-78

Indexfelder

author_variant	c d l cd cdl s g m sg sgm
matchkey_str	article:15586804:2016----::lrptnseclssrbssucomsn
hierarchy_sort_str	2016
bklnumber	42.15
publishDate	2016
allfields	10.1007/s12015-016-9695-z doi (DE-627)SPR023690429 (SPR)s12015-016-9695-z-e DE-627 ger DE-627 rakwb eng 570 610 ASE 42.15 bkl Luzzani, Carlos D. verfasserin aut Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Mesenchymal stem cells (MSC) have been extensively studied over the past years for the treatment of different diseases. Most of the ongoing clinical trials currently involve the use of MSC derived from adult tissues. This source may have some limitations, particularly with therapies that may require extensive and repetitive cell dosage. However, nowadays, there is a staggering growth in literature on a new source of MSC. There is now increasing evidence about the mesenchymal differentiation from pluripotent stem cell (PSC). Here, we summarize the current knowledge of pluripotent-derived mesenchymal stem cells (PD-MSC). We present a historical perspective on the subject, and then discuss some critical questions that remain unanswered. Pluripotent stem cells (dpeaa)DE-He213 Embryonic stem cells (dpeaa)DE-He213 Cell reprogramming (dpeaa)DE-He213 Mesenchymal stem cells (dpeaa)DE-He213 Mesenchymal stromal cells (dpeaa)DE-He213 Differentiation (dpeaa)DE-He213 Pluripotent-derived mesenchymal stem cells (dpeaa)DE-He213 iPS-derived mesenchymal stem cells (dpeaa)DE-He213 Epithelial-to-mesenchymal transition (dpeaa)DE-He213 EMT (dpeaa)DE-He213 Miriuka, Santiago G. verfasserin aut Enthalten in Stem cell reviews New York, NY : Springer, 2005 13(2016), 1 vom: 05. Nov., Seite 68-78 (DE-627)494833777 (DE-600)2197218-7 1558-6804 nnns volume:13 year:2016 number:1 day:05 month:11 pages:68-78 https://dx.doi.org/10.1007/s12015-016-9695-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2005 42.15 ASE AR 13 2016 1 05 11 68-78
spelling	10.1007/s12015-016-9695-z doi (DE-627)SPR023690429 (SPR)s12015-016-9695-z-e DE-627 ger DE-627 rakwb eng 570 610 ASE 42.15 bkl Luzzani, Carlos D. verfasserin aut Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Mesenchymal stem cells (MSC) have been extensively studied over the past years for the treatment of different diseases. Most of the ongoing clinical trials currently involve the use of MSC derived from adult tissues. This source may have some limitations, particularly with therapies that may require extensive and repetitive cell dosage. However, nowadays, there is a staggering growth in literature on a new source of MSC. There is now increasing evidence about the mesenchymal differentiation from pluripotent stem cell (PSC). Here, we summarize the current knowledge of pluripotent-derived mesenchymal stem cells (PD-MSC). We present a historical perspective on the subject, and then discuss some critical questions that remain unanswered. Pluripotent stem cells (dpeaa)DE-He213 Embryonic stem cells (dpeaa)DE-He213 Cell reprogramming (dpeaa)DE-He213 Mesenchymal stem cells (dpeaa)DE-He213 Mesenchymal stromal cells (dpeaa)DE-He213 Differentiation (dpeaa)DE-He213 Pluripotent-derived mesenchymal stem cells (dpeaa)DE-He213 iPS-derived mesenchymal stem cells (dpeaa)DE-He213 Epithelial-to-mesenchymal transition (dpeaa)DE-He213 EMT (dpeaa)DE-He213 Miriuka, Santiago G. verfasserin aut Enthalten in Stem cell reviews New York, NY : Springer, 2005 13(2016), 1 vom: 05. Nov., Seite 68-78 (DE-627)494833777 (DE-600)2197218-7 1558-6804 nnns volume:13 year:2016 number:1 day:05 month:11 pages:68-78 https://dx.doi.org/10.1007/s12015-016-9695-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2005 42.15 ASE AR 13 2016 1 05 11 68-78
allfields_unstemmed	10.1007/s12015-016-9695-z doi (DE-627)SPR023690429 (SPR)s12015-016-9695-z-e DE-627 ger DE-627 rakwb eng 570 610 ASE 42.15 bkl Luzzani, Carlos D. verfasserin aut Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Mesenchymal stem cells (MSC) have been extensively studied over the past years for the treatment of different diseases. Most of the ongoing clinical trials currently involve the use of MSC derived from adult tissues. This source may have some limitations, particularly with therapies that may require extensive and repetitive cell dosage. However, nowadays, there is a staggering growth in literature on a new source of MSC. There is now increasing evidence about the mesenchymal differentiation from pluripotent stem cell (PSC). Here, we summarize the current knowledge of pluripotent-derived mesenchymal stem cells (PD-MSC). We present a historical perspective on the subject, and then discuss some critical questions that remain unanswered. Pluripotent stem cells (dpeaa)DE-He213 Embryonic stem cells (dpeaa)DE-He213 Cell reprogramming (dpeaa)DE-He213 Mesenchymal stem cells (dpeaa)DE-He213 Mesenchymal stromal cells (dpeaa)DE-He213 Differentiation (dpeaa)DE-He213 Pluripotent-derived mesenchymal stem cells (dpeaa)DE-He213 iPS-derived mesenchymal stem cells (dpeaa)DE-He213 Epithelial-to-mesenchymal transition (dpeaa)DE-He213 EMT (dpeaa)DE-He213 Miriuka, Santiago G. verfasserin aut Enthalten in Stem cell reviews New York, NY : Springer, 2005 13(2016), 1 vom: 05. Nov., Seite 68-78 (DE-627)494833777 (DE-600)2197218-7 1558-6804 nnns volume:13 year:2016 number:1 day:05 month:11 pages:68-78 https://dx.doi.org/10.1007/s12015-016-9695-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2005 42.15 ASE AR 13 2016 1 05 11 68-78
allfieldsGer	10.1007/s12015-016-9695-z doi (DE-627)SPR023690429 (SPR)s12015-016-9695-z-e DE-627 ger DE-627 rakwb eng 570 610 ASE 42.15 bkl Luzzani, Carlos D. verfasserin aut Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Mesenchymal stem cells (MSC) have been extensively studied over the past years for the treatment of different diseases. Most of the ongoing clinical trials currently involve the use of MSC derived from adult tissues. This source may have some limitations, particularly with therapies that may require extensive and repetitive cell dosage. However, nowadays, there is a staggering growth in literature on a new source of MSC. There is now increasing evidence about the mesenchymal differentiation from pluripotent stem cell (PSC). Here, we summarize the current knowledge of pluripotent-derived mesenchymal stem cells (PD-MSC). We present a historical perspective on the subject, and then discuss some critical questions that remain unanswered. Pluripotent stem cells (dpeaa)DE-He213 Embryonic stem cells (dpeaa)DE-He213 Cell reprogramming (dpeaa)DE-He213 Mesenchymal stem cells (dpeaa)DE-He213 Mesenchymal stromal cells (dpeaa)DE-He213 Differentiation (dpeaa)DE-He213 Pluripotent-derived mesenchymal stem cells (dpeaa)DE-He213 iPS-derived mesenchymal stem cells (dpeaa)DE-He213 Epithelial-to-mesenchymal transition (dpeaa)DE-He213 EMT (dpeaa)DE-He213 Miriuka, Santiago G. verfasserin aut Enthalten in Stem cell reviews New York, NY : Springer, 2005 13(2016), 1 vom: 05. Nov., Seite 68-78 (DE-627)494833777 (DE-600)2197218-7 1558-6804 nnns volume:13 year:2016 number:1 day:05 month:11 pages:68-78 https://dx.doi.org/10.1007/s12015-016-9695-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2005 42.15 ASE AR 13 2016 1 05 11 68-78
allfieldsSound	10.1007/s12015-016-9695-z doi (DE-627)SPR023690429 (SPR)s12015-016-9695-z-e DE-627 ger DE-627 rakwb eng 570 610 ASE 42.15 bkl Luzzani, Carlos D. verfasserin aut Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Mesenchymal stem cells (MSC) have been extensively studied over the past years for the treatment of different diseases. Most of the ongoing clinical trials currently involve the use of MSC derived from adult tissues. This source may have some limitations, particularly with therapies that may require extensive and repetitive cell dosage. However, nowadays, there is a staggering growth in literature on a new source of MSC. There is now increasing evidence about the mesenchymal differentiation from pluripotent stem cell (PSC). Here, we summarize the current knowledge of pluripotent-derived mesenchymal stem cells (PD-MSC). We present a historical perspective on the subject, and then discuss some critical questions that remain unanswered. Pluripotent stem cells (dpeaa)DE-He213 Embryonic stem cells (dpeaa)DE-He213 Cell reprogramming (dpeaa)DE-He213 Mesenchymal stem cells (dpeaa)DE-He213 Mesenchymal stromal cells (dpeaa)DE-He213 Differentiation (dpeaa)DE-He213 Pluripotent-derived mesenchymal stem cells (dpeaa)DE-He213 iPS-derived mesenchymal stem cells (dpeaa)DE-He213 Epithelial-to-mesenchymal transition (dpeaa)DE-He213 EMT (dpeaa)DE-He213 Miriuka, Santiago G. verfasserin aut Enthalten in Stem cell reviews New York, NY : Springer, 2005 13(2016), 1 vom: 05. Nov., Seite 68-78 (DE-627)494833777 (DE-600)2197218-7 1558-6804 nnns volume:13 year:2016 number:1 day:05 month:11 pages:68-78 https://dx.doi.org/10.1007/s12015-016-9695-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2005 42.15 ASE AR 13 2016 1 05 11 68-78
language	English
source	Enthalten in Stem cell reviews 13(2016), 1 vom: 05. Nov., Seite 68-78 volume:13 year:2016 number:1 day:05 month:11 pages:68-78
sourceStr	Enthalten in Stem cell reviews 13(2016), 1 vom: 05. Nov., Seite 68-78 volume:13 year:2016 number:1 day:05 month:11 pages:68-78
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Pluripotent stem cells Embryonic stem cells Cell reprogramming Mesenchymal stem cells Mesenchymal stromal cells Differentiation Pluripotent-derived mesenchymal stem cells iPS-derived mesenchymal stem cells Epithelial-to-mesenchymal transition EMT
dewey-raw	570
isfreeaccess_bool	false
container_title	Stem cell reviews
authorswithroles_txt_mv	Luzzani, Carlos D. @@aut@@ Miriuka, Santiago G. @@aut@@
publishDateDaySort_date	2016-11-05T00:00:00Z
hierarchy_top_id	494833777
dewey-sort	3570
id	SPR023690429
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR023690429</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519163820.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12015-016-9695-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR023690429</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12015-016-9695-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.15</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Luzzani, Carlos D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Mesenchymal stem cells (MSC) have been extensively studied over the past years for the treatment of different diseases. Most of the ongoing clinical trials currently involve the use of MSC derived from adult tissues. This source may have some limitations, particularly with therapies that may require extensive and repetitive cell dosage. However, nowadays, there is a staggering growth in literature on a new source of MSC. There is now increasing evidence about the mesenchymal differentiation from pluripotent stem cell (PSC). Here, we summarize the current knowledge of pluripotent-derived mesenchymal stem cells (PD-MSC). We present a historical perspective on the subject, and then discuss some critical questions that remain unanswered.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pluripotent stem cells</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Embryonic stem cells</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cell reprogramming</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mesenchymal stem cells</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mesenchymal stromal cells</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Differentiation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pluripotent-derived mesenchymal stem cells</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">iPS-derived mesenchymal stem cells</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Epithelial-to-mesenchymal transition</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">EMT</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miriuka, Santiago G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Stem cell reviews</subfield><subfield code="d">New York, NY : Springer, 2005</subfield><subfield code="g">13(2016), 1 vom: 05. Nov., Seite 68-78</subfield><subfield code="w">(DE-627)494833777</subfield><subfield code="w">(DE-600)2197218-7</subfield><subfield code="x">1558-6804</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">day:05</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:68-78</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12015-016-9695-z</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.15</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="b">05</subfield><subfield code="c">11</subfield><subfield code="h">68-78</subfield></datafield></record></collection>
author	Luzzani, Carlos D.
spellingShingle	Luzzani, Carlos D. ddc 570 bkl 42.15 misc Pluripotent stem cells misc Embryonic stem cells misc Cell reprogramming misc Mesenchymal stem cells misc Mesenchymal stromal cells misc Differentiation misc Pluripotent-derived mesenchymal stem cells misc iPS-derived mesenchymal stem cells misc Epithelial-to-mesenchymal transition misc EMT Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells
authorStr	Luzzani, Carlos D.
ppnlink_with_tag_str_mv	@@773@@(DE-627)494833777
format	electronic Article
dewey-ones	570 - Life sciences; biology 610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1558-6804
topic_title	570 610 ASE 42.15 bkl Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells Pluripotent stem cells (dpeaa)DE-He213 Embryonic stem cells (dpeaa)DE-He213 Cell reprogramming (dpeaa)DE-He213 Mesenchymal stem cells (dpeaa)DE-He213 Mesenchymal stromal cells (dpeaa)DE-He213 Differentiation (dpeaa)DE-He213 Pluripotent-derived mesenchymal stem cells (dpeaa)DE-He213 iPS-derived mesenchymal stem cells (dpeaa)DE-He213 Epithelial-to-mesenchymal transition (dpeaa)DE-He213 EMT (dpeaa)DE-He213
topic	ddc 570 bkl 42.15 misc Pluripotent stem cells misc Embryonic stem cells misc Cell reprogramming misc Mesenchymal stem cells misc Mesenchymal stromal cells misc Differentiation misc Pluripotent-derived mesenchymal stem cells misc iPS-derived mesenchymal stem cells misc Epithelial-to-mesenchymal transition misc EMT
topic_unstemmed	ddc 570 bkl 42.15 misc Pluripotent stem cells misc Embryonic stem cells misc Cell reprogramming misc Mesenchymal stem cells misc Mesenchymal stromal cells misc Differentiation misc Pluripotent-derived mesenchymal stem cells misc iPS-derived mesenchymal stem cells misc Epithelial-to-mesenchymal transition misc EMT
topic_browse	ddc 570 bkl 42.15 misc Pluripotent stem cells misc Embryonic stem cells misc Cell reprogramming misc Mesenchymal stem cells misc Mesenchymal stromal cells misc Differentiation misc Pluripotent-derived mesenchymal stem cells misc iPS-derived mesenchymal stem cells misc Epithelial-to-mesenchymal transition misc EMT
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Stem cell reviews
hierarchy_parent_id	494833777
dewey-tens	570 - Life sciences; biology 610 - Medicine & health
hierarchy_top_title	Stem cell reviews
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)494833777 (DE-600)2197218-7
title	Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells
ctrlnum	(DE-627)SPR023690429 (SPR)s12015-016-9695-z-e
title_full	Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells
author_sort	Luzzani, Carlos D.
journal	Stem cell reviews
journalStr	Stem cell reviews
lang_code	eng
isOA_bool	false
dewey-hundreds	500 - Science 600 - Technology
recordtype	marc
publishDateSort	2016
contenttype_str_mv	txt
container_start_page	68
author_browse	Luzzani, Carlos D. Miriuka, Santiago G.
container_volume	13
class	570 610 ASE 42.15 bkl
format_se	Elektronische Aufsätze
author-letter	Luzzani, Carlos D.
doi_str_mv	10.1007/s12015-016-9695-z
dewey-full	570 610
author2-role	verfasserin
title_sort	pluripotent stem cells as a robust source of mesenchymal stem cells
title_auth	Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells
abstract	Abstract Mesenchymal stem cells (MSC) have been extensively studied over the past years for the treatment of different diseases. Most of the ongoing clinical trials currently involve the use of MSC derived from adult tissues. This source may have some limitations, particularly with therapies that may require extensive and repetitive cell dosage. However, nowadays, there is a staggering growth in literature on a new source of MSC. There is now increasing evidence about the mesenchymal differentiation from pluripotent stem cell (PSC). Here, we summarize the current knowledge of pluripotent-derived mesenchymal stem cells (PD-MSC). We present a historical perspective on the subject, and then discuss some critical questions that remain unanswered.
abstractGer	Abstract Mesenchymal stem cells (MSC) have been extensively studied over the past years for the treatment of different diseases. Most of the ongoing clinical trials currently involve the use of MSC derived from adult tissues. This source may have some limitations, particularly with therapies that may require extensive and repetitive cell dosage. However, nowadays, there is a staggering growth in literature on a new source of MSC. There is now increasing evidence about the mesenchymal differentiation from pluripotent stem cell (PSC). Here, we summarize the current knowledge of pluripotent-derived mesenchymal stem cells (PD-MSC). We present a historical perspective on the subject, and then discuss some critical questions that remain unanswered.
abstract_unstemmed	Abstract Mesenchymal stem cells (MSC) have been extensively studied over the past years for the treatment of different diseases. Most of the ongoing clinical trials currently involve the use of MSC derived from adult tissues. This source may have some limitations, particularly with therapies that may require extensive and repetitive cell dosage. However, nowadays, there is a staggering growth in literature on a new source of MSC. There is now increasing evidence about the mesenchymal differentiation from pluripotent stem cell (PSC). Here, we summarize the current knowledge of pluripotent-derived mesenchymal stem cells (PD-MSC). We present a historical perspective on the subject, and then discuss some critical questions that remain unanswered.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2005
container_issue	1
title_short	Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells
url	https://dx.doi.org/10.1007/s12015-016-9695-z
remote_bool	true
author2	Miriuka, Santiago G.
author2Str	Miriuka, Santiago G.
ppnlink	494833777
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s12015-016-9695-z
up_date	2024-07-03T20:40:22.352Z
_version_	1803591847619067904
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR023690429</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519163820.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12015-016-9695-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR023690429</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12015-016-9695-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.15</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Luzzani, Carlos D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Mesenchymal stem cells (MSC) have been extensively studied over the past years for the treatment of different diseases. Most of the ongoing clinical trials currently involve the use of MSC derived from adult tissues. This source may have some limitations, particularly with therapies that may require extensive and repetitive cell dosage. However, nowadays, there is a staggering growth in literature on a new source of MSC. There is now increasing evidence about the mesenchymal differentiation from pluripotent stem cell (PSC). Here, we summarize the current knowledge of pluripotent-derived mesenchymal stem cells (PD-MSC). We present a historical perspective on the subject, and then discuss some critical questions that remain unanswered.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pluripotent stem cells</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Embryonic stem cells</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cell reprogramming</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mesenchymal stem cells</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mesenchymal stromal cells</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Differentiation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pluripotent-derived mesenchymal stem cells</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">iPS-derived mesenchymal stem cells</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Epithelial-to-mesenchymal transition</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">EMT</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miriuka, Santiago G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Stem cell reviews</subfield><subfield code="d">New York, NY : Springer, 2005</subfield><subfield code="g">13(2016), 1 vom: 05. Nov., Seite 68-78</subfield><subfield code="w">(DE-627)494833777</subfield><subfield code="w">(DE-600)2197218-7</subfield><subfield code="x">1558-6804</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">day:05</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:68-78</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12015-016-9695-z</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.15</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="b">05</subfield><subfield code="c">11</subfield><subfield code="h">68-78</subfield></datafield></record></collection>
score	7.4012003

Nicht das Richtige dabei?

Schreiben Sie uns!

Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?